Skip to content

Author

J. Ritz

We have 5 of 107 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Effects of post-transplant cyclophosphamide on immune reconstitution after haploidentical and HLA-matched transplant.

Post-transplant cyclophosphamide (PTCy) is increasingly used for graft-versus-host disease (GVHD) prophylaxis in both HLA-matched (matched-PTCy) and haplotype-mismatched (haplo-PTCy) hematopoietic stem cell transplantation (HCT), but the effects of PTCy on immune reconstitution in different donor settings remain incomp...

Michela Ansuinelli, H. Kim, Francesco Malfona et al. · 0 citations
Open access Sep 2026

Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial

Teclistamab, a B cell maturation antigen-targeting bispecific antibody, has demonstrated substantial activity in relapsed multiple myeloma (MM), particularly in earlier lines of therapy, and may have higher efficacy in high-risk smoldering MM (HR-SMM) with a more functional immune system. In the randomized phase 2 Immu...

Omar Nadeem, D. M. Cordas dos Santos, Sophie Magidson et al. · 0 citations
Sep 2026

Spatially confined IL-12 programs CAR-NK through mTORC1 to coordinate antitumor immune networks.

Solid tumors evade immunotherapy because of immunosuppressive microenvironments that limit immune cell persistence and function. Although interleukin-12 (IL-12) potently activates antitumor immunity, its clinical use has been constrained by systemic toxicity. Here we engineered a CAR natural killer (NK) cell platform t...

Mubin Tarannum, K. Dinh, Mila Stanojevic et al. · 0 citations
Aug 2026

Tumor-tropic E. coli engineered as living T and NK cell engagers

LIME bridged effector and tumor cells, induced transcriptional programs of T cell activation, metabolism and proliferation, and enhanced cytotoxicity across cancer cell lines and patient-derived organoids, establishing LIME as a versatile living therapeutic platform for programmable, tumor-restricted immune orchestrati...

Shao-Bo Yang, Anna Clara Bader, S. Sendker et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.